Evaluating the natural history of Charcot Marie Tooth Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the natural history and genotype-phenotype correlations of various types of Charcot Marie Tooth Disease (CMT), including CMT1B, CMT2A, CMT4A, and CMT4C. The study will utilize the newly developed CMT Pediatric Scale and Minimal Dataset to measure impairment and track longitudinal changes in patients over a five-year period. Conducted by the Inherited Neuropathies Consortium, it involves multiple prestigious institutions across North America and Europe, focusing on gathering comprehensive data on CMT. The study will include patients with documented pathogenic variants or those with a family history of CMT.

Why it matters

Who can join: the full rules

Inclusion Criteria

General Criteria

1\. All patients must agree to take part in the study and sign a consent form. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Patients:

1. Must have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).
2. OR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.
3. In cases where clear links are not available, genetic confirmation is required.
4. Patients who have a variant(s) of uncertain significance on clinical laboratory reports may still be included if:
5. The variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
6. OR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
7. OR the principal investigator and the site investigator agree that the variant(s) is (are) likely disease-causing.

Controls

1. Must not have a peripheral neuropathy, as determined by the site investigator.
2. Must have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Exclusion Criteria

Patients:

1. Patient does not wish to participate or does not sign a consent form.
2. Patient has a different potential cause for their neuropathy AND no disease-causing variant(s).
3. Deemed inappropriate by the Site PI.

Where it's running

• Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting
• Stanford University
  Palo Alto, California, United States Recruiting
• University of Colorado Hospital
  Aurora, Colorado, United States Recruiting
• University of Connecticut/Connecticut Children's Medical Center
  Hartford, Connecticut, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• University of Iowa
  Iowa City, Iowa, United States Recruiting

Study contacts

• Principal investigator: Michael E Shy, MD — University of Iowa
• Study coordinator: Nicole M Kressin, MSN, RN
• Email: UICMTClinic@uiowa.edu
• Phone: 319-384-6362

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tremor in Charcot–Marie–Tooth disease

  Try to characterize tremor in adults with Charcot–Marie–Tooth (CMT) disease using surface electromyography, accelerometers, a clinical exam and questionnaires to see how tremor affects daily life.

  Recruiting University Medical Center Goettingen · Göttingen, Lower Saxony · NCT07570459

• MORC2 gene changes and how they relate to nerve and developmental symptoms

  This project will try to see if specific changes in the MORC2 gene explain why some people develop Charcot–Marie–Tooth nerve problems while others have broader developmental delays, growth impairment, facial differences, and neuropathy.

  Recruiting at 12 sites Hospices Civils de Lyon · Besançon and 11 other locations · NCT07038239

• High-tech rehabilitation program for adults with chronic neuromuscular diseases

  This trial will test whether a high-tech rehab program using robotic systems, virtual reality, and balance platforms works as well as traditional rehab to reduce fatigue and improve function in adults with chronic neuromuscular diseases.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Genova and 6 other locations · NCT06881979

• Observing walking patterns in patients with neuromuscular diseases

  This study is testing how walking patterns change in people with neuromuscular diseases and whether wearable sensors can help track their daily activity and fatigue levels.

  Recruiting IRCCS Eugenio Medea · Bosisio Parini, Lecco and 1 other locations · NCT06666816

• Understanding Pyrimidine and Purine Metabolism Disorders

  This study is trying to learn more about pyrimidine and purine metabolism disorders by comparing affected people with their healthy family members to see what factors might influence their condition.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06092346

• Understanding Charcot-Marie-Tooth Disease through patient data

  This study is collecting information from people with Charcot-Marie-Tooth Disease to better understand their experiences and help improve future treatments.

  Recruiting Hereditary Neuropathy Foundation · New York, New York · NCT05902351

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.